Effect of low-density lipoproteins, mevinolin, and G proteins on Ca2+ response in cultured chick atrial cells.
Growth of cells from atria of embryonic chick hearts 14 days in ovo in medium supplemented with lipoprotein-depleted serum (LPDS) results in an increase in total cell cholesterol, enhanced parasympathetic responsiveness (7), and decreased sympathetic responsiveness (1). These effects were reversed by the hydroxymethyl glutaryl CoA reductase inhibitor, mevinolin. In these studies, comparison of cell growth in medium supplemented with fetal calf serum (FCS) and LPDS demonstrated that, after growth with LPDS, the ability of Ca2+ and the Ca2+ channel agonist, BAY K 8644, to enhance the amplitude of contraction decreased by 25 and 50%, respectively. These effects of growth in LPDS were reversed by incubation with mevinolin. LPDS had no effect on either Ca2+ channel number as measured by (+)-[5-methyl-3H]PN200-110 binding or Ca2+ current density as measured by the whole cell patch method. Treatment of cells grown in LPDS with pertussis toxin, which inactivates alpha o and alpha i, returned the contractile response to 10(-7) M BAY K 8644 to control levels. Pertussis toxin had no effect on the contractile response or adenosine 3',5'-cyclic monophosphate levels in control cells grown in FCS alone. These data suggest that alterations in the relative levels of alpha o and alpha s in cells grown in LPDS may play a role in regulating the contractile response to Ca2+ channel agonists and to exogenous Ca2+.
Tan
W
W
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115.
Barnett
J V
JV
Pietrobon
D
D
Hehn
G
G
Greiser
C
C
Marsh
J D
JD
Galper
J B
JB
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D015220:Calcium Channels / Q000378:metabolism; D002417:Cattle / Q000097:blood / Q000196:embryology; D002478:Cells, Cultured; D002642:Chick Embryo; D004095:Dihydropyridines / Q000378:metabolism; D005110:Extracellular Space / Q000378:metabolism; D005312:Fetal Blood; D019204:GTP-Binding Proteins / Q000502:physiology*; D006325:Heart Atria; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D008148:Lovastatin / Q000494:pharmacology*; D009206:Myocardium / Q000166:cytology / Q000378:metabolism*; D037342:Pertussis Toxin; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D015220:Calcium Channels; D004095:Dihydropyridines; D008077:Lipoproteins, LDL; D010566:Virulence Factors, Bordetella; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D008148:Lovastatin; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins; D002118:Calcium